138 related articles for article (PubMed ID: 35798647)
1. BCG Administration after Prior Radiation Treatment for Prostate Cancer.
Durant AM; Chang YH; Faraj KS; Tyson MD
Clin Genitourin Cancer; 2022 Dec; 20(6):591-597. PubMed ID: 35798647
[TBL] [Abstract][Full Text] [Related]
2. Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer.
Bree KK; Hensley PJ; Brooks NA; Matulay J; Li R; Nogueras Gonzalez GM; Navai N; Grossman HB; Matin SF; Dinney CPN; Kamat AM
BJU Int; 2021 Nov; 128(5):568-574. PubMed ID: 33484074
[TBL] [Abstract][Full Text] [Related]
3. Intravesical bacillus Calmette-Guerin immunotherapy after previous prostate radiotherapy for high-grade non-muscle-invasive bladder cancer.
Rao MV; Ellimoottil C; Sondej T; Flanigan RC; Quek ML
Urol Oncol; 2013 Aug; 31(6):857-61. PubMed ID: 21868262
[TBL] [Abstract][Full Text] [Related]
4. Oncologic outcomes of intravesical therapy in the management of nonmuscle invasive bladder cancer with variant histology.
Lone Z; Benidir T; Wood A; Campbell RA; Alaghehbandan R; Li J; Haber GP; Eltemamy M; Haywood SC; Weight CJ; Lee BH; Almassi N
Urol Oncol; 2024 Mar; 42(3):71.e1-71.e7. PubMed ID: 38135626
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
Miyake M; Tatsumi Y; Matsumoto H; Nagao K; Matsuyama H; Inamoto T; Azuma H; Yasumoto H; Shiina H; Fujimoto K;
BJU Int; 2018 May; 121(5):764-773. PubMed ID: 29281857
[TBL] [Abstract][Full Text] [Related]
6. Anti-inflammatory use may not negatively impact oncologic outcomes following intravesical BCG for high-grade non-muscle-invasive bladder cancer.
Singla N; Haddad AQ; Passoni NM; Meissner M; Lotan Y
World J Urol; 2017 Jan; 35(1):105-111. PubMed ID: 27194044
[TBL] [Abstract][Full Text] [Related]
7. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS).
Witjes JA; Palou J; Soloway M; Lamm D; Kamat AM; Brausi M; Persad R; Buckley R; Colombel M; Böhle A
BJU Int; 2013 Oct; 112(6):742-50. PubMed ID: 23452187
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety outcomes of lower dose BCG compared to intravesical chemotherapy in non-muscle-invasive bladder cancer: A network meta-analysis.
Kawada T; Yanagisawa T; Bekku K; Laukhtina E; von Deimling M; Chlosta M; Pradere B; Teoh JY; Babjuk M; Araki M; Shariat SF
Urol Oncol; 2023 Jun; 41(6):261-273. PubMed ID: 37137745
[TBL] [Abstract][Full Text] [Related]
9. Intravesical BCG treatment causes a long-lasting reduction of recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer.
Thiel T; Ryk C; Renström-Koskela L; Steineck G; Schumacher MC; Wiklund NP; de Verdier PJ
World J Urol; 2019 Jan; 37(1):155-163. PubMed ID: 29905887
[TBL] [Abstract][Full Text] [Related]
10. [A Randomized Controlled Study of Intravesical Instillation Therapy of Bacillus Calmette-Guérin vs. Epirubicinin Treating Non-muscular Invasive Bladder Cancer].
Yang WX; Shao YX; Hu X; Xiong SC; Liu Y; Li X
Sichuan Da Xue Xue Bao Yi Xue Ban; 2021 Mar; 52(2):326-333. PubMed ID: 33829710
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non-muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guérin Immunotherapy.
Mayr R; Eckstein M; Wirtz RM; Santiago-Walker A; Baig M; Sundaram R; Carcione JC; Stoehr R; Hartmann A; Bolenz C; Burger M; Otto W; Erben P; Breyer J
Eur Urol; 2022 Jun; 81(6):606-614. PubMed ID: 35351346
[TBL] [Abstract][Full Text] [Related]
12. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
[TBL] [Abstract][Full Text] [Related]
13. Intra-arterial chemotherapy combined with intravesical chemotherapy compared with intravesical BCG immunotherapy retrospectively in high-risk non-muscle-invasive bladder cancer after transurethral resection of the bladder tumor.
Huang B; Huang G; Li W; Chen L; Mao X; Chen J
J Cancer Res Clin Oncol; 2021 Jun; 147(6):1781-1788. PubMed ID: 33222014
[TBL] [Abstract][Full Text] [Related]
14. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
[TBL] [Abstract][Full Text] [Related]
15. Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis.
Houghton BB; Chalasani V; Hayne D; Grimison P; Brown CS; Patel MI; Davis ID; Stockler MR
BJU Int; 2013 May; 111(6):977-83. PubMed ID: 23253618
[TBL] [Abstract][Full Text] [Related]
16. Impact of prior intravesical bacillus Calmette-Guerin therapy on the effectiveness of pembrolizumab for patients with metastatic urothelial carcinoma.
Taoka R; Kobayashi T; Hidaka Y; Abe H; Ito K; Kojima T; Kato M; Kanda S; Hatakeyama S; Matsui Y; Matsushita Y; Naito S; Shiga M; Miyake M; Muro Y; Nakanishi S; Kato Y; Shibuya T; Hayashi T; Yasumoto H; Yoshida T; Uemura M; Kamiyama M; Morita S; Ogawa O; Nishiyama H; Kitamura H; Sugimoto M;
Urol Oncol; 2022 Mar; 40(3):107.e1-107.e9. PubMed ID: 34454824
[TBL] [Abstract][Full Text] [Related]
17. Determining optimal maintenance schedules for adjuvant intravesical bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer: a systematic review and network meta-analysis.
Huang Z; Liu H; Wang Y; Zhang C; Xu T
Curr Med Res Opin; 2017 Aug; 33(8):1379-1387. PubMed ID: 28471272
[TBL] [Abstract][Full Text] [Related]
18. Non-maintenance intravesical Bacillus Calmette-Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study.
Miyake M; Iida K; Nishimura N; Miyamoto T; Fujimoto K; Tomida R; Matsumoto K; Numakura K; Inokuchi J; Morizane S; Yoneyama T; Matsumura Y; Abe T; Inoue M; Yamada T; Terada N; Hirao S; Uemura M; Matsushita Y; Taoka R; Kobayashi T; Kojima T; Matsui Y; Kitamura H; Nishiyama H;
BMC Cancer; 2021 Mar; 21(1):266. PubMed ID: 33706705
[TBL] [Abstract][Full Text] [Related]
19. Polymorphism in autophagy gene ATG2B is not associated with bladder cancer recurrence after intravesical Bacillus Calmette-Guerin (BCG) immunotherapy in Asian patients.
Zang Z; Lim YK; Chan YH; Raman L; Esuvaranathan K; Chiong E; Mahendran R
Urol Oncol; 2021 Apr; 39(4):238.e1-238.e7. PubMed ID: 33250346
[TBL] [Abstract][Full Text] [Related]
20. Association of Bacillus Calmette-Guerin shortages with bladder cancer recurrence: A single-center retrospective study.
Lee S; Lim B; You D; Hong B; Hong JH; Kim CS; Ahn H; Jeong IG
Urol Oncol; 2020 Nov; 38(11):851.e11-851.e17. PubMed ID: 32800440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]